Kairos Pharma Ltd. (KAPA)
Kairos Pharma Ltd. Statistics
Share Statistics
Kairos Pharma Ltd. has - shares outstanding. The number of shares has increased by null% in one year.
Shares Outstanding | - |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Institutions (%) | n/a |
Shares Floating | - |
Failed to Deliver (FTD) Shares | 1.25K |
FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 9.61K, so 0.07% of the outstanding shares have been sold short.
Short Interest | 9.61K |
Short % of Shares Out | 0.07% |
Short % of Float | 0.16% |
Short Ratio (days to cover) | 0.13 |
Valuation Ratios
The PE ratio is -14.9 and the forward PE ratio is -6.43. Kairos Pharma Ltd.'s PEG ratio is -0.21.
PE Ratio | -14.9 |
Forward PE | -6.43 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | -43.12 |
P/FCF Ratio | 333.25 |
PEG Ratio | -0.21 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kairos Pharma Ltd..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.06, with a Debt / Equity ratio of 0.
Current Ratio | 0.06 |
Quick Ratio | 0.06 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | -17.49 |
Financial Efficiency
Return on equity (ROE) is 2.89% and return on capital (ROIC) is 273.8%.
Return on Equity (ROE) | 2.89% |
Return on Assets (ROA) | -1.88% |
Return on Capital (ROIC) | 273.8% |
Revenue Per Employee | $undefined |
Profits Per Employee | $undefined |
Employee Count | undefined |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 3.08, so Kairos Pharma Ltd.'s price volatility has been higher than the market average.
Beta | 3.08 |
52-Week Price Change | null% |
50-Day Moving Average | 1.26 |
200-Day Moving Average | null |
Relative Strength Index (RSI) | 41.06 |
Average Volume (20 Days) | 2.43M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -1.71M |
Net Income | -1.81M |
EBITDA | -1.55M |
EBIT | n/a |
Earnings Per Share (EPS) | -0.17 |
Balance Sheet
The company has 93K in cash and 0 in debt, giving a net cash position of 93K.
Cash & Cash Equivalents | 93K |
Total Debt | 0 |
Net Cash | 93K |
Retained Earnings | -6.32M |
Total Assets | 5M |
Working Capital | 3.07M |
Cash Flow
In the last 12 months, operating cash flow was 81K and capital expenditures 0, giving a free cash flow of 81K.
Operating Cash Flow | 81K |
Capital Expenditures | 0 |
Free Cash Flow | 81K |
FCF Per Share | 0.01 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
KAPA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -18.68% |
FCF Yield | 0.65% |
Analyst Forecast
The average price target for KAPA is $9, which is 889% higher than the current price. The consensus rating is "Buy".
Price Target | $9 |
Price Target Difference | 889% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Scores
Altman Z-Score | 1.7 |
Piotroski F-Score | 3 |